Free Trial

Allergy Therapeutics (LON:AGY) Reaches New 1-Year High - Here's What Happened

Allergy Therapeutics logo with Medical background

Key Points

  • Allergy Therapeutics shares reached a new 52-week high, trading at GBX 8.50 ($0.11) during mid-day trading, surpassing the previous close of GBX 8.10.
  • The company has a market capitalization of £417.78 million with a notably high debt-to-equity ratio of 835.48.
  • Allergy Therapeutics specializes in the treatment of allergic disorders and offers aluminium-free immunotherapy vaccines across several European markets.
  • Looking to export and analyze Allergy Therapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Allergy Therapeutics plc (LON:AGY - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11), with a volume of 57317 shares trading hands. The stock had previously closed at GBX 8.10 ($0.11).

Allergy Therapeutics Stock Up 2.9%

The firm's 50-day simple moving average is GBX 7.70 and its 200 day simple moving average is GBX 6.95. The company has a market cap of £430.07 million, a P/E ratio of -8.43, a PEG ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63.

About Allergy Therapeutics

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Featured Stories

Should You Invest $1,000 in Allergy Therapeutics Right Now?

Before you consider Allergy Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.

While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines